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by CMR in Inﬁltrative Heart Disease
François-Pierre Mongeon, MD, SM,*† Michael Jerosch-Herold, PHD,‡
Ota´vio Rizzi Coelho-Filho, MD, MPH,*§ Ron Blankstein, MD,* Rodney H. Falk, MD,*
Raymond Y. Kwong, MD, MPH*
Boston, Massachusetts; Montreal, Quebec, Canada; and Campinas, São Paulo, Brazil
O B J E C T I V E S The aim of this study was to perform direct quantiﬁcation of myocardial extracellular
volume fraction (ECF) with T1-weighted cardiac magnetic resonance (CMR) imaging in patients
suspected to have inﬁltrative heart disease.
B A C KG ROUND Inﬁltrative heart disease refers to accumulation of abnormal substances within the
myocardium. Qualitative assessment of late gadolinium enhancement (LGE) remains the most com-
monly used method for CMR evaluation of patients suspected with myocardial inﬁltration. This
technique is widely available and can be performed in a reproducible and standardized manner.
However, the degree of extracellular matrix expansion due to myocardial inﬁltration in the intercellular
space has, to date, not been amenable to noninvasive quantiﬁcation with LGE.
METHOD S We performed 3-T CMR in 38 patients (mean age 68  15 years) who were referred for
assessment of inﬁltrative heart disease and also in 9 healthy volunteers as control subjects. The T1
quantiﬁcation by Look-Locker gradient-echo before and after contrast determined segmental myocar-
dial partition coefﬁcients. The ECF was obtained by referencing the tissue partition coefﬁcient for
gadolinium to the plasma volume fraction in blood, derived from serum hematocrit. Cine CMR and LGE
imaging in matching locations were also performed.
R E S U L T S Seventeen patients (45%) had cardiac amyloidosis (CA) (biopsy-conﬁrmed or clinically
highly probable), 20 (53%) had a non-amyloid cardiomyopathy, and 1 had lysosomal storage disease.
Median global ECF was substantially higher in CA patients (0.49) compared with non-amyloid
cardiomyopathy patients (0.33, p  0.0001) and volunteers (0.24, p  0.0001). The ECF strongly
correlated with visually assessed segmental LGE (r  0.80, p  0.0001) and LV mass index (r  0.69,
p  0.0001), reﬂecting severity of myocardial inﬁltration. In patients with CA, ECF was highest in
segments with LGE, although it remained elevated in segments without qualitative LGE.
CONC L U S I O N S The CMR ECF quantiﬁcation identiﬁed substantial expansion of the interstitial
space in patients with CA compared with volunteers. Further studies using this technique for diagnosis
and assessment of the severity of myocardial inﬁltration are warranted. (J Am Coll Cardiol Img 2012;
5:897–907) © 2012 by the American College of Cardiology Foundation
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898nfiltrative heart disease refers to accumulation of
abnormal substances within the myocardium (1).
In imaging, some of these uncommon cardiomy-
opathies present with increased myocardial wall
thickness, whereas others present with chamber
dilation and wall thinning (1). Amyloidosis, Fabry
disease (2), and mucopolysaccharidosis (3) are ex-
amples of conditions that present with increased left
ventricular (LV) mass and wall thickness (1). Hy-
pertensive heart disease might also mimic morpho-
See page 908
logic, functional, and electrocardiographic features
of infiltrative heart disease. Hypertrophic cardiomy-
opathy is another important and common differen-
tial diagnosis adding to the challenge of recognizing
infiltrative heart disease. Clinical history and elec-
trocardiogram (ECG) might be helpful.
Low ECG voltages are suggestive of car-
diac amyloidosis (CA), but ECG voltages
might be normal or increased in other
infiltrative heart diseases (1). A definitive
diagnosis usually relies on endomyocardial
biopsy, which is invasive and subject to
sampling error.
Growing evidence suggests that tissue
characterization by cardiac magnetic reso-
nance (CMR), in particular the use of late
gadolinium enhancement (LGE) imaging,
can provide evaluation of myocardial infil-
tration (1). Among infiltrative heart dis-
eases, the pattern of LGE in CA has been
most studied (4–9) and shown to have prog-
nostic implications (6,7,10). In smaller patient
eries, LGE has proven useful for recognition of Fabry
isease (2) and of Danon disease (11), among others.
yocardial fibrosis, identified by LGE, is also present
n patients with LV hypertrophy, regardless of diag-
osis (12).
Qualitative assessment of LGE remains the most
ommonly used method for CMR evaluation of
atients with suspected myocardial infiltration. It is
idely available and can be performed in a repro-
ucible and standardized manner. However, the
egree of extracellular matrix expansion due to
yocardial infiltration in the intercellular space has,
o date, not been amenable to noninvasive quanti-
cation with LGE. In the particular case of CA,
GE was significantly associated with fibrosis but
ot with the extent of amyloid infiltration in a
istologic comparison study (5). In cases of myo-
r
lar
ionardial infiltration, accumulation of gadolinium is ehought to result from expansion of the extracellular
atrix, not only by fibrotic replacement but mostly
y accumulation of insoluble proteins (1,13). Such
ccumulation is diffuse and might be difficult to
uantify by LGE imaging alone. There is no
niversal threshold that defines fibrosis or infiltra-
ion by LGE. Contrast relies on signal intensity
ifferences between normal and abnormal myocar-
ium, a difference that might not exist in a diffuse
rocess. Signal intensity also depends on the selec-
ion of an inversion time that nulls the signal of a
yocardial reference region.
T1 mapping techniques identify areas of myocar-
ium where gadolinium accumulates by relying on
ts T1 shortening effect (14,15). Thornhill et al.
16,17) previously described that the linear relation-
hip between the T1 relaxation of myocardium and
lood pool reflects the distribution of gadolinium
nd allows calculation of the partition coefficient for
adolinium in myocardial infarction. Arheden et al.
18) further reported that myocardial extracellular
olume fraction within infarcted tissue can be di-
ectly determined by normalizing the partition co-
fficient to (1  blood hematocrit). This technique
as identified extracellular matrix expansion in the
bsence of LGE in dilated cardiomyopathy (19)
nd congenital heart disease (20). Another study
sing an equivalent technique provided correlation
etween CMR measurements and histological find-
ngs in aortic stenosis and hypertrophic cardiomy-
pathy (21). In CA, accumulation of gadolinium
esults from expansion of the myocardial extracel-
ular matrix, either from fibrosis or interstitial ac-
umulation of amyloid protein (4,5,13). Maceira et
l. (4) have identified that subendocardial T1 was
horter in CA, corresponding to areas of interstitial
xpansion and of LGE. These abnormal gadolin-
um kinetics have been associated with worse prog-
osis in patients with CA (22).
In the current paper, our group performed direct
uantification of myocardial extracellular volume
raction (ECF) by CMR in patients suspected to
ave infiltrative cardiomyopathy. The technique
sed in the current study extended the work of
thers by inclusion of up to 4 total time points,
efore and after administration of gadolinium con-
rast agent, to improve the fitting of linear relation-
hip for the measurement of partition coefficient
nd subsequently ECF. We hypothesized that mea-
urement of the ECF can provide a quantitative
arker of disease burden in patients with proven
nd suspected infiltrative cardiomyopathy and aid inA B B R E V I A T I O N S
A N D A C R O N YM S
Gd partition coefficient fo
gadolinium
CA cardiac amyloidosis
CMR cardiac magnetic
resonance
ECFmyocardial extracellu
fraction
ECG electrocardiogram
LGE late gadolinium
enhancement
LV left ventricular
LVEF left ventricular ejectvaluating the magnitude of adverse tissue remod-
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899eling in comparison with healthy volunteers and in
adjunct to LGE. We further hypothesized that
ECF will be associated with markers of infiltrative
heart disease, including LV mass index, LV systolic
and diastolic dysfunction, and LGE.
M E T H O D S
Patient subjects. We performed CMR on 38 con-
secutive patients referred for evaluation of infiltra-
tive heart disease between December 2008 and
September 2010. Patients were excluded from per-
forming CMR in any of the following conditions:
1) decompensated heart failure; 2) hemodynamic
instability; 3) severe claustrophobia despite use of
sedatives; 4) presence of metallic hazards; and
5) estimated glomerular filtration rate 30 ml/min/
1.73 m2 within 30 days before CMR. The CMR
eferral was based on the following reasons: 1) suspicion
f infiltrative heart disease due to increased wall
hickness by echocardiography and/or voltage cri-
eria for LV hypertrophy by ECG (n  26); 2)
suspicion of myocardial infiltration in patients with
known systemic infiltrative disease such as amyloid-
osis (n 4); and 3) assessment of severity of cardiac
involvement in patients with known CA (n  8)
(Table 1). Control subjects were 9 healthy volun-
teers who underwent 3.0-T CMR with identical
imaging parameters in the setting of a prior study
(20). Healthy volunteers had no history of heart
disease, hypertension, or any other risk factors for
coronary artery disease, and they did not undergo
echocardiography and ECG. All subjects, cases and
controls, gave informed consent to CMR study and
administration of gadolinium. For patients, no gado-
linium was administered for the sole purpose of this
study. Retrospective review of clinical, imaging, and
pathology records of patients was approved by the
Partners Healthcare Institutional Review Board.
Clinical, electrocardiographic, and echocardiographic
data. Clinical history was collected at the time of
MR imaging. The ECGs closest in time to the
MR were reviewed with regard to rhythm, pres-
nce of low voltages, presence of R-wave in lead
1–V3, and bundle branch block, blinded to all
clinical and study data. Low voltages were defined
as the sum of the amplitude of the S-wave in lead
V1 and of R-wave in lead V5 or V6 15 mm (23).
chocardiographic studies were reviewed offline for
iastolic function assessed with the peak velocities
f the mitral E and A waves and the pulmonary
eins S and D waves by pulse-wave Doppler and of
he E’-wave of the lateral and septal mitral annulusy tissue Doppler imaging. A decreasing peak
elocity of the E’-wave of the mitral annulus by
issue Doppler imaging was used as an indicator of
rogressively more restrictive cardiomyopathy (24).
The final diagnosis for each patient was estab-
ished after completion of all clinical evaluations
nd independently from ECF data. Final diagnoses
ell in the following categories (Tables 1 and 2): 1)
onfirmed CA by endomyocardial biopsy; 2) highly
robable CA; or 3) non-amyloid cardiomyopathy.
or patients who underwent endomyocardial bi-
psy, the final diagnosis was established by the
istopathologic interpretation of an experienced
athologist. Confirmed CA was based on endo-
yocardial biopsy evidence with Congo Red and
ulphated Alcian Blue stains or immuno-peroxidase
taining for transthyretin and immuno-fluorescence
taining for immunoglobulins IgG, IgM, IgA,
appa, lambda, and protein A. For patients who did
ot undergo endomyocardial biopsy, the final diag-
osis is the one retained by the treating cardiologist
f the patient on the basis of symptoms, ECG, or
chocardiographic or CMR findings. The diagnosis
f highly probable CA was reached on the basis of
ccepted evidence of CA by clinical history, echo-
Table 1. Indications for CMR and Final Diagnosis After Complet
in 38 Patients
Final Diagnosis
Indication for Referral to CM
Known CA
Unexplained
Thickened LV or
ECG Voltage
Criteria for LVH
S
In
CA
By biopsy 7 7
By clinical diagnosis 1 1
Non-amyloid CMP 0 18
Lysosomal storage disease 0 0
Total 8 (17%) 26 (55%)
CA  cardiac amyloidosis; CMP  cardiomyopathy; CMR  cardiac magnetic r
ECG  electrocardiogram; LVH  left ventricular hypertrophy; LV  left ventri
Table 2. Final Diagnosis in Patients With Non-Amyloid
Cardiomyopathy
Frequency (%)
Hypertensive cardiomyopathy 9 (45%)
Cardiomyopathy of undeﬁned etiology by
clinical workup
6 (30%)
Cardiomyopathy of undeﬁned etiology by
biopsy
3 (15%)
Ventricular arrhythmias 1 (5%)
Hypertrophic cardiomyopathy 1 (5%)e Clinical Evaluation
R
Total
ystemic
ﬁltrative
Disease
0 14 (37%)
1 3 (8%)
2 20 (53%)
1 1 (5%)
4 (9%) 38
esonance imaging;Total 20
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900cardiography, and laboratory testing (25) combined
with a LGE pattern consistent with the description
by Maceira et al. (4). Patients with no histopatho-
logic evidence of amyloidosis on biopsy and without
any evidence of myocardial infiltration by LGE
imaging were considered to have non-amyloid car-
diomyopathy. We have made every effort to clarify
the diagnosis, but it could not be definitively estab-
lished in 11 patients, even with an endomyocardial
biopsy in 3 of them. The detailed final diagnoses of
patients with non-amyloid cardiomyopathy are out-
lined in Table 2. No patient in this group could be
considered to have a normal heart on the basis of
symptoms, ECG, or echocardiographic or biopsy
findings.
CMR protocol. All patients were studied supine in a
.0-T CMR system (Tim Trio, Siemens Medical
ystems, Malvern, Pennsylvania). For LV size and
ine function, steady-state free-precession sequence
typical repetition time: 3.4 ms; echo time: 1.2 ms;
emporal resolution, 40 to 50 ms; in-plane spatial
esolution 1.5 to 1.8 mm and 1.8 to 2.1 mm, on the
asis of the field of view) was performed in multiple
arallel short-axis planes (8-mm-thick without
pacing). An inversion recovery fast gradient-echo
equence, triggered every other heartbeat, was used
o assess for LGE in short-axis locations, matching
Figure 1. ECF Quantiﬁcation
The method of myocardial extracellular volume fraction (ECF) quan
batic inversion pulse is illustrated. (A) Images from the mid left ven
(B) Determination of T1 and R1 by exponential ﬁtting of the signal-
spond to signal intensities obtained at time points displayed in (A)
the linear relationship between R1 for myocardium versus R1 for th
point is derived from a signal intensity versus time curve as display
coefﬁcient by (1  hematocrit). IR  inversion recovery.hose for cine imaging (8-mm-thick, 0-mm spac-
ng) and 3 radial long-axis planes. Acquisition of
GE images began within 5 to 10 min after bolus
dministration of a cumulative dose of 0.15
mol/kg of gadolinium diethylenetriamine pent-
cetic acid (Magnevist, Berlex, Wayne, New Jer-
ey). The T1 measurements were performed with a
ook-Locker sequence (19,20) with a nonslice-
elective adiabatic inversion pulse, followed by seg-
ented gradient-echo acquisition for 17 cardiac phas-
s/times after inversion, spread over 1 to 2 cardiac
ycles (temporal resolution 80 ms pre-contrast, and 45
s post-contrast, slice thickness 8 mm, repetition
ime3 RR intervals pre-contrast and 2 RR intervals
ost-contrast). The Look-Locker sequence was re-
eated in the same mid LV short-axis slice once
efore and 3 additional times after the injection of
adolinium spanning a 30-min period. With model
imulations, Jerosch-Herold et al. (19) showed that
he apparent distribution volume of gadolinium agrees
ithin 1% with the extracellular volume for times 3
in from the beginning of the contrast bolus injec-
ion, for myocardial blood flows above 0.5 ml/min/g.
or that reason, the post-contrast T1 measurements
ere started no earlier than 3 min after contrast bolus
njection.
tion by the Look-Locker gradient-echo sequence with an adia-
lar (LV) short-axis location are shown (only 4 phases displayed).
nsity versus time curve for 1 myocardial segment. Numbers corre-
Derivation of the partition coefﬁcient by calculating the slope of
ood pool from all R1 measurements (0.83). Each corresponding
n (B). The ECF is then determined by multiplying the partitiontiﬁca
tricu
inte
. (C)
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901Quantiﬁcation of global and segmental ECF. The
CF was quantified as reported previously and is
llustrated in Figure 1 (19,20). For each Look-
Locker sequence the endo- and epicardial borders
of the LV were traced and divided into 6 standard
segments (QMass MR 7.1 software, Medis, the
Netherlands). The signal intensity versus time
curves for each segment and the blood pool were
used to determine segmental T1 through fitting to
an analytical expression for the inversion recovery
and correction for the radiofrequency pulse altera-
tion of the inversion recovery. The reciprocal of T1
(R1  1/T1) was used to plot the myocardial R1
against the R1 in the blood pool and calculate the
slope by linear regression, with all measurement
points. The slope of the linear relationship defines
the partition coefficient for gadolinium (Gd). The
ECF values of all 6 myocardial segments were
obtained by multiplying each of the segmental Gd
by (1  hematocrit in percent/100). Global ECF
or each patient or healthy volunteer was then
alculated by averaging the 6 myocardial segmental
alues.
Cine CMR and LGE assessment. Manually traced epi-
ardial and endocardial borders of matching short-
xis cine locations at end-systole and end-diastole
ere used to determine the left ventricular ejection
raction (LVEF), LV end-diastolic volume index,
V end-systolic volume index, and LV myocardial
ass (end-diastole only). The LVEF was measured
y standard Simpson’s rule with summation of
hort-axis locations with no interslice spacing. The
xtent of LGE was assessed by assigning a score of
or 0 according to the presence or absence of LGE
n the subendocardial and subepicardial halves of
ach myocardial segment, with the American Heart
ssociation 17-segment model and blinded to ECF
ata. An LGE score was obtained by summing the
core of each segment (0 or 1). The maximum
ossible score was 33, because the apical cap (seg-
ent 17) was not considered to have a subendocar-
ial portion.
Statistical analysis. Continuous data were expressed
s mean  SD or median (interquartile range)
when appropriate. Categorical data were expressed
as frequency and proportions. Continuous data
were compared between groups with t test or
Wilcoxon rank sum test according to the distribu-
tion. Categorical data were compared with a Fisher
exact test when possible and with a chi-square test
otherwise. A Kruskall-Wallis test was used for
comparison of ECF across diagnostic categories. To
account for multiple between-group comparisons,an adjusted p value of 0.0125 was considered
significant. When segmental ECF values were in-
cluded in the analysis, a linear mixed effects model
was used to account for the fact that segmental
ECF values are correlated within each patient.
Spearman rank correlation was used to obtain
correlation coefficients between continuous vari-
ables of interest.
R E S U L T S
Baseline characteristics. We studied 39 patients who
et the inclusion criteria and used CMR studies
ith ECF measurements from 9 healthy volunteers.
ne subject was excluded due to poor CMR image
uality. The indications for referral to CMR and
he final diagnoses after completion of clinical
valuation of the remaining 38 patients are outlined
n Table 1. The most common indication for CMR
as further investigation of unexplained increased
V wall thickness by echocardiography or voltage
riteria for LV hypertrophy by ECG. In this cohort
f 38 patients, 17 (45%) were diagnosed to have
A. Among them, 14 (37%) were biopsy-
onfirmed CA, and 3 (8%) were highly probable
A on the basis of clinical grounds. One patient
as found to have cardiac involvement by a lyso-
omal storage disease (Hunter disease) on the basis
f extracardiac manifestations and typical valvular
nfiltration; this patient did not undergo endomyo-
ardial biopsy. No evidence of myocardial infiltra-
ion could be found in the remaining 20 (53%)
atients in whom it was suspected (Tables 1 and 2).
Clinical, electrocardiographic, echocardiographic,
and CMR characteristics of the study population
are outlined in Table 3. Compared with patients
with non-amyloid cardiomyopathy and with
healthy control subjects, patients with CA were
older and had worse LV systolic function, higher
LV mass index, and marked LGE burden in both
the atria and ventricles. The LV E/A ratio and the
septal wall E/E’ ratio were higher in patients with
CA compared with patients with non-amyloid
cardiomyopathy.
ECF. Figure 2 presents the median ECF values for
each diagnostic group. The median ECF for
healthy subjects was 0.24, whereas it was 0.33, 0.41,
and 0.49 for patients with non-amyloid cardiomy-
opathy, highly probable CA, and confirmed CA,
respectively. The ECF was not statistically different
between patients with confirmed CA and those
with highly probable CA (p  0.13). We found
wide margins of difference in median ECF between
0
d
t
g
t
s
p
l
Table 1.
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902patients with CA, non-amyloid cardiomyopathy,
and healthy control subjects (p  0.0001 and p 
.0001, respectively). The patient with Hunter’s
isease was not included in this analysis, because
his patient alone could not form a valid comparison
roup. However, it is noteworthy that the ECF in
his patient (0.34) was higher than in healthy
ubjects (0.24) in absence of LGE.
Global and segmental LGE. In all subjects (n  47),
ECF demonstrated a strong correlation with the
LGE score in a corresponding mid-LV slice (r 
0.80, p  0.0001) (Fig. 3A). However, examination
of the vertical axis in Figure 3A showed that some
subjects without LV myocardial LGE had an elevated
ECF. The LV myocardial LGE was present in all
patients with CA by qualitative evaluation (Table 3),
Characteristics of the Study Population
CA
(n  17)
Non-Amyloid
Cardiomyopathy
(n  20)
Healthy
Volunteers
(n  9)
79 6* 61 13†‡ 45 11
2 (12%)† 7 (35%) 6 (67%)
10 (59%)† 12 (60%)† 0
40 4 40 5 41 2
m 8 (53%) 5 (26%) na
8 (53%) 3 (16%)§ na
12 (80%) 19 (100%) na
2.9 1.9 1.2 1.5§ na
time (ms) 188 52 191 98 na
l (cm/s) 5.2 1.0 7.9 3.5 na
(cm/s) 4.3 1.2 6.2 1.9 na
14 5 12 3 na
17 4 15 5 na
resonance
l/m2) 94 24† 91 37¶ 65 8
/m2) 50 22* 47 35† 20 6
48 12* 53 15† 69 9
g/m2) 101 29* 72 43† 42 9
12 (71%)* 0‡ 0
16 (94%)* 3 (15%)‡ 0
12 (71%)* 0‡ 0
17 6* 0.7 1.6‡ 0
or frequency (%). Electrocardiograms were available in 15 patients with CA and
on-amyloid cardiomyopathy. The patient with Hunter’s disease is excluded.
re available in 11 patients with CA and in 16 patients with non-amyloid
0.001 for comparison with healthy volunteers; †p  0.01 for comparison with
 0.001 for comparison with patients with CA; §p  0.05 for comparison with
0.01 for comparison with patients with CA; ¶p  0.05 for comparison with
olume; ESV  end-systolic volume; LGE  late gadolinium enhancement; LVEF 
n fraction; na  not available; RV  right ventricle; other abbreviations as inindicating substantial expansion of the extracel- plular space. In the subgroup of patients with CA,
ECF is highest in segments with LGE, but it also
is elevated in myocardial segments without LGE
(Fig. 3B).
ECF and markers of cardiac inﬁltration. The ECF
correlates strongly with LV mass index (r  0.69,
 0.0001) (Fig. 4A). It also correlates negatively
with LVEF (r  0.55, p  0.0002) (Fig. 4B) and
with the peak velocity of the E’-wave of both the
lateral (Fig. 4C) and septal (Fig. 4D) wall by tissue
Doppler echocardiography.
D I S C U S S I O N
Summary of results. In this retrospective cross-
sectional case-control study, we have measured the
extracellular volume fraction in patients with known
and suspected infiltrative heart disease. Most in-
cluded patients either had CA or a non-amyloid
cardiomyopathy, forming the 2 comparative patient
groups in our study, along with healthy volunteers.
Measurement of ECF indicates that patients with
amyloidosis and cardiac involvement have the high-
est degree of myocardial extracellular matrix expan-
sion, even in segments where LGE cannot be
qualitatively seen. Flacke et al. (26) reported that
the partition coefficient in patients with acute and
chronic myocardial infarction averaged 0.91 and
0.78, in the acute infarct and chronic regions,
respectively—which suggests an ECF of 0.55 and
0.47, respectively, assuming an average hematocrit
of 40%. In patients with CA, the ECF approached
similar levels as in acute myocardial infarction in
regions with LGE but was lower in regions without
LGE, although still significantly higher than in the
patients with non-amyloid cardiomyopathy. These
observations suggest that measurement of the ECF
might allow a finer gradation of adverse tissue
remodeling than is possible by qualitative assess-
ment of LGE. Increasing values of ECF are asso-
ciated with markers of increased myocardial infil-
tration, such as LV mass index and LVEF (25), and
with indexes of restrictive cardiomyopathy, such as
the E’ wave peak velocity (24). Greater ECF values
are associated with higher LGE scores, both re-
flecting greater extracellular matrix expansion. The
ECF also identifies abnormal characteristics in
myocardium not displaying LGE. This allows ap-
preciation of otherwise unrecognized infiltration
and might lead to an earlier diagnosis.
Healthy volunteers. Study of healthy subjects al-
owed for establishment of the median ECF in thatTable 3. Baseline
Age (yrs)
Female
Hypertension
Hematocrit (%)
ECG
Non-sinus rhyth
Low voltages
R-wave V1–V3
Echocardiography
LV E/A ratio
LV deceleration
LV E’ lateral wal
LV E’ septal wall
E/E’ lateral wall
E/E’ septal wall
Cardiac magnetic
LVEDV index (m
LVESV index (ml
LVEF (%)
LV mass index (
LGE
Atria
LV
RV
LV LGE score
Values are mean SD
in 19 patients with n
Echocardiograms we
cardiomyopathy. *p 
healthy volunteers; ‡p
patients with CA; p 
healthy volunteers.
EDV  end-diastolic v
left ventricular ejectioopulation (0.24) (20). A similar control group was
c
h
d
p
h
f
h
yop
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903used in the current study. This ECF value is
comparable to that reported (range 18.4% to 29.1%)
in another study of healthy subjects with a similar
technique (27). The low ECF in healthy subjects
corresponds to a longer post-contrast T1 relaxation
time. Tightly packed normal cardiomyocytes do not
allow for much accumulation of gadolinium in the
interstitium.
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Figure 2. Comparison of Median MECVF Between Diagnostic Gr
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tive interpretation (LGE score of 0) had an MECVF value 0.24. (B)
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ave myocardial infiltration was hypertensive car-
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resentation with LV hypertrophy. As patients age,
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eart disease arises, because they both cause in-
Non AMYL CMP
0.33
Volunteer
0.24
ll-Wallis p < 0.0001
 = 0.0001
p = 0.0003
s
atients with cardiac amyloidosis (AMYL). There is a large margin
p value 0.0125 is considered signiﬁcant for between group
nd-whisker plot, the central box represents the values from the
sents the median. The vertical lines extend from the minimum to
athy.
Cardiac Amyloidosis
Late Gadolinium Enhancement
p = 0.05
0.30
0.40
0.50
0.60
No LGE LGE
GE
volume fraction (MECVF) and late gadolinium enhancement (LGE)
47). Note that 23 (82%) of 28 patients with no LGE by qualita-
parison of MECVF in myocardial segments with and without LGEsis
ical
1
uska
001
p
oup
in p
). A
ox-a
epreEx
tr
ac
el
lu
la
r V
o
lu
m
e 
Fr
ac
tio
n 
(%
)
B
d L
lar
(n 
Com
p
p
T
i
h
n
R
o
l
i
c
r
h
a
i
p
m
a
r
d
t
t
t
w
p
(
E
t
m
bb
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 9 , 2 0 1 2
S E P T E M B E R 2 0 1 2 : 8 9 7 – 9 0 7
Mongeon et al.
ECF in Infiltrative Heart Disease
904creased myocardial wall thickness. Late gadolinium
enhancement can also occur in the hypertensive
patient (12). However, our results suggest that the
degree of ECF expansion is substantially lower than
in CA. It is conceivable that similar observations
could be made for hypertrophic cardiomyopathy
patients, although our data do not allow further
testing of this hypothesis. Flett et al. (21), however,
reported extracellular matrix expansion in hypertro-
phic cardiomyopathy. The remainder of patients
with non-amyloid cardiomyopathy presented with a
suspicion of infiltrative heart disease, although no
specific diagnosis could be reached after all clinically
justifiable investigations, including endomyocardial
biopsy in 3 patients. No convincing evidence of
myocardial infiltration could be found in any of
these patients. The presence of clinical heart failure,
abnormal ECG or echocardiogram, or significant
arrhythmias ruled out that these patients have a
normal heart. A median ECF of 0.33 (range 0.25 to
0.41) in these 11 patients also supports that they
have a cardiomyopathy, in comparison with healthy
volunteers (median ECF  0.24).
ECF quantiﬁcation. In this study, we have applied a
reviously described technique to measure the ex-
ansion of myocardial extracellular matrix (19).
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Figure 4. Correlations Between MECVF and Markers of Myocard
Correlations between MECVF and (A) LV mass index, (B) LV ejection
and (D) of the LV septal wall by tissue Doppler echocardiography. Ahis technique uses a repetition time equal to 3 RR cntervals, making it very insensitive to variation in
eart rate in the clinical setting. In fact, there was
o significant association between the pre-contrast
1 values and the heart rate of the patient. The use
f the partition coefficient also adjusts for the blood
evels of gadolinium. Therefore, the estimate of T1
s independent of the dose of gadolinium and of its
learance from the blood pool, which will vary with
enal function. The method also does not depend
eavily on the exact timing of the T1 measurement
fter infusion of gadolinium, in contrast to LGE
maging, and the T1 measurement protocol pro-
osed by Maceira et al. (4). In our protocol, T1
easurements are only acquired after a 3-min delay
fter gadolinium injection to allow for an equilib-
ium between gadolinium concentration in myocar-
ium and blood. This can be repeated multiple
imes over the course of the CMR study to optimize
he accuracy of the partition coefficient determina-
ion by linear regression analysis. A previous study,
ith kinetic parameters determined from a first pass
erfusion imaging in each patient, used simulations
19) to conclude that equilibrium conditions for
CF estimation are met within 3 min for typical
issue perfusion and gadolinium clearance rates. A
ore recent study has shown that ECF did not
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905bolus injection (27) and left open the question of
whether a 3-min delay is sufficient for contrast
equilibrium to take place. We note that our findings
of a significantly abnormal ECF in cardiomyopathy
and amyloid become more marked if the first
post-contrast T1 measurement, acquired as early as
3 min after injection, is eliminated from the deter-
mination of ECF. The ECF changed by8% (p
0.002) higher without this first post-contrast T1
measurement. This suggests that under some con-
ditions—such as a markedly expanded extracellular
space, as found in amyloid, or with reduced tissue
perfusion—a delay of 3 min might be too short to
achieve equilibrium. Overall, acquisition of 4 T1
measurements (1 before and 3 after gadolinium
injection) adds between 5 and 15 min to the study,
depending on whether a single slice or multiples
levels are imaged.
The equivalent protocol proposed by Flett et al.
(21) was based on only 2 T1 measurements. It requires
an infusion of gadolinium lasting up to 90 min, during
which the patient is removed from the scanner. Both
the bolus and infusion methods were found to give
stable ECF measures between 12 and 50 min after
contrast injection, in a recent direct comparison (27).
The study by Flett et al. (21) provided robust histo-
logical confirmation that the volume of distribution of
gadolinium derived from T1 measurements matches
the collagen volume fraction. Other techniques used
in studies using T1 mapping (14,15) are subject to
variability in measurements due to heart rate and to
the dose, rate of injection, and washout of gadolinium.
These techniques, however, can provide pixel-by-pixel
Figure 5. Complementary Use of LGE and MECVF in Patients W
Late gadolinium enhancement (LGE) images obtained with a standa
other heartbeat in 2 patients with biopsy proven cardiac amyloidos
diac amyloidosis are present. Accordingly, myocardial extracellular v
appreciate myocardial inﬁltration, if at all present. It seems that LGE
marked inﬁltration in all segments (MECVF in healthy volunteers T1 maps.Late gadolinium enhancement. Late gadolinium en-
hancement has emerged as an important tool for the
CMR diagnosis of infiltrative heart disease and of
CA in particular (1,9). Late gadolinium enhance-
ment was also associated with adverse survival
outcomes in patients with CA (6,7,10); LGE is a
robust and accessible technique that is a fundamen-
tal part of the CMR evaluation of patients with
cardiomyopathy (28). However, in the particular
case of CA, LGE imaging is faced with particular
challenges. A pathologic study reported that the
extent of amyloid deposition was not associated
with LGE finding in any region (5). Late gadolin-
ium enhancement corresponded more accurately to
areas of fibrosis (5). Homogenous or diffuse depo-
sition of amyloid protein in the myocardium can
preclude automated detection of differences in sig-
nal intensity on the basis of an arbitrary threshold.
For that reason, we have relied on qualitative
assessment of LGE. Identification of extracellular
matrix expansion in areas with questionable LGE
can help resolve diagnostic dilemmas. Examples of
the complementary use of LGE and ECF in diag-
nosis of cardiac infiltration are presented in Figure 5.
Late gadolinium enhancement is also sensitive to
selection of the inversion time and to observer
interpretation. Selection of inversion time can be
difficult in CA, due to the rapid myocardial uptake
of gadolinium. This has even been reported as a
diagnostic clue to the diagnosis of CA (8). Prog-
nostic information associated with the presence of
LGE has been obtained in patients with advanced
disease (25). Maceira et al. (22) have reported a
ardiac Amyloidosis
nversion recovery fast gradient echo sequence triggered every
A) Patient #1. Multiple areas of enhancement consistent with car-
me fraction (MECVF) is elevated. (B) Patient #2. It is difﬁcult to
present in the anterior wall. However, segmental MECVF suggests
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906dial T1 mapping and survival in patients with CA.
Late gadolinium enhancement was not associated
with outcomes in their study (22). Therefore, a
technique sensitive to changes in T1, such as ECF,
might eventually be shown to better reflect the
severity of cardiac involvement and might be asso-
ciated with prognosis.
Study limitations. Our study is limited by a small
ample size, which is largely due to the rarity of
nfiltrative heart disease. Because CMR has become
art of routine assessment of CA, the group of
atients with infiltrative heart disease consisted
ostly of patients with advanced, clinically evident
A. This potentially reflects a referral bias influ-
nced by the current diagnostic need and increased
sage of CMR in the clinical diagnosis of infiltra-
ive heart disease. We cannot assess the degree of
yocardial extracellular matrix expansion in pa-
ients at an earlier stage of CA. A subset of 11
atients in this study were left with a nonspecific
iagnosis, even after endomyocardial biopsy in 3 of
hem. Endomyocardial biopsies were not obtained
or all patients, reflecting a parsimonious and di-
inishing use of this technique in the clinical
ork-up of patients suspected to have myocardial
nfiltration. When available, histological diagnosis
f infiltrative cardiomyopathy relied on clinically
btained right ventricular endomyocardial biopsies.
iopsies of the LV myocardium studied with ECF
ere not available. However, infiltrative heart dis-
ases are diffuse processes. For that reason, we have
ocused ECF measurement to a middle short-axis
lice and not to the entire myocardium. The ECF
uantification requires administration of gadolin-
um, which can be limited by renal insufficiency,
hich complicates primary and secondary forms of
myloidosis (25). The processing of CMR images
o derive ECF remains labor intensive, but the
echnique might resolve diagnostic uncertainty andal. Glycogen storage diseases pre- 196 –204.etermination of ECF through pre- and post-
ontrast T1 measurements requires the establish-
ent of an equilibrium state for the contrast distri-
ution between blood and tissue. This imposes
inimum delay for the first post-contrast T1 mea-
urement after contrast injection. Because contrast
lears rapidly from the blood pool in patients with
myloidosis, a delay of 3 min was chosen for this
rotocol to allow observation of large R1 changes
elative to the native R1. If the earliest post-contrast
easurement is excluded from the myocardial ECF
stimation, then we obtain a myocardial ECF that
s on average 6% to 8% higher. This difference did
ot alter the main results when the patient groups
ere compared. Finally, LGE was quantified as
resent or absent in the subendocardial and subepi-
ardial halves of each myocardial segment. Due to
he diffuse distribution of LGE, formal quantifica-
ion of LGE on the basis of signal intensity could
ot be used.
C O N C L U S I O N S
Extracellular volume fraction measured by contrast-
enhanced CMR is elevated in patients with clini-
cally suspected myocardial infiltration. The highest
extracellular volume expansion was found in pa-
tients with CA. This technique has the potential to
provide a quantitative assessment of myocardial
infiltration with CMR beyond qualitative interpre-
tation. Further validation of the diagnostic utility of
this technique in a larger subset of patients and at
an earlier stage of infiltration is warranted. Mea-
surement of ECF before and after treatment would
also be worthy of further study.
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